Wingspire Equipment Finance Closes $70 Million Sale-Leaseback to Support U.S. Expansion for Global Paper Manufacturer
The tissue paper manufacturer has also made a shift in CapEx planning by proactively working with domestic capital providers, as it has historically funded its operations through its parent company. The sale-leaseback proved highly successful by delivering large proceeds, an extended term, and a compelling fixed rate.
'Our client has prioritized expansion and growth in production. They are leveraging acquisitions and greenfield investments in the U.S. to strengthen their position in a rapidly evolving and consolidating industry. We were delighted to earn their trust to complete this large and strategically important transaction. The proceeds will help fund another paper machine for the facility, already the largest and most automated in the parent company's worldwide operations,' said Jeffrey Okano, Senior Vice President of Originations at Wingspire Equipment Finance.
Wingspire Equipment Finance continues to leverage its immense lending capacity to deliver large-scale capital solutions for its clients. This is especially crucial in a landscape of economic uncertainty and tightening credit standards.
About Wingspire Equipment Finance:
Wingspire Equipment Finance is a leading provider of equipment financing solutions, dedicated to empowering middle-market companies with flexible and innovative financial solutions. With a focus on client success and industry expertise, Wingspire Equipment Finance is dedicated to delivering strategic capital solutions that drive long-term success for its clients. Wingspire Equipment Finance is the equipment financing arm of Wingspire Capital, a portfolio company of Blue Owl Capital Corporation (NYSE: OBDC). OBDC is externally managed by Blue Owl Credit Advisors LLC, an indirect affiliate of Blue Owl Capital, Inc. (NYSE: OWL). Blue Owl Capital, Inc. is a global alternative asset manager with $284 billion of assets under management as of June 30th, 2025.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Wire
an hour ago
- Business Wire
Introducing Cambridge Forum 2025: Tech for Good
CAMBRIDGE, England--(BUSINESS WIRE)-- Cambridge Forum 2025, themed 'Tech for Good', is set to bring together global technology leaders, development innovators, policymakers, entrepreneurs, and academics in Cambridge this September. This two-day event discusses technology as a force for inclusive empowerment and positive social impact. Our Vision: From Underserved to Unstoppable At Cambridge Forum, we believe that technology can transform lives—especially in underserved communities. Rooted in Cambridge's academic and innovation ecosystem, we will foster collaboration across technology, development, academia, policy, and the private sector to bring solutions to the world's pressing challenges. Taking place in the historic city of Cambridge—a global hub for intellectual discovery—the Forum aims to be a permanent platform for inclusive collaboration across disciplines, sectors, and geographies. 'We believe the world's toughest challenges can't be solved in silos. Cambridge Forum offers a shared space to design, build, and scale innovation for good,' said Dr. Ehab Shanti, Founding Director of Cambridge Forum. 'AI undoubtedly presents enormous derivative challenges, but it also creates significant opportunities. Cambridge Forum will explore both,' he added. Cambridge Forum 2025 will feature a high-impact line-up of world-class speakers and changemakers, including: Marty Neumeier – Highly influential American author, designer, and business advisor focused on the intersection of design, branding, and innovation will deliver a session on 'Goodness as Corporate DNA'. Jaideep Prabhu – Co-author of Jugaad Innovation: Think Frugal, Be Flexible, will deliver a session on" Frugal Innovation: Leveraging Digital Public Infrastructure for Inclusive Artificial Intelligence'. Dr. Gareth Corbett, Chief Medical Officer, Onion AI will discuss, 'Tech for Good, The Case of AI and Health'. Henning Grosse Ruse Khan - Professor of Law at the University of Cambridge will discuss, 'Can We Regulate AI to Prevent Harm?'. Why It Matters In a time of global complexity and rapid technological advancement, we aim to ensure no one is left behind. By fostering cross-sector collaboration and offering practical tools, Cambridge Forum helps turn big ideas into real-world solutions to address the world's most pressing issues. About Cambridge Forum Cambridge Forum is a training and knowledge-sharing event that provides participants with a unique opportunity to learn. Through practical training and real-world applications, we will discuss how to harness advanced technology in AI and Insurtech to address the world's most pressing challenges and serve underserved communities.
Business Wire
2 hours ago
- Business Wire
Anocca Raises SEK 440 Million to Advance Clinical Trial Targeting Pancreatic Cancer
SÖDERTÄLJE, Sweden--(BUSINESS WIRE)--Anocca AB ('Anocca' or the 'Company'), a leading clinical-stage T-cell immunotherapy company, has successfully raised SEK ~440 million (USD ~46 million) in financing. The additional capital will be used to drive the continued progress of VIDAR-1, Anocca's gene-edited TCR-T cell therapies targeting mutant KRAS in pancreatic cancer, through early-stage clinical development, as well as progress Anocca's preclinical pipeline. The financing was led by Mellby Gård with strong support from AMF, Ramsbury and existing shareholders, alongside new investors. Recruitment is now open for Phase I of the multi-centre trial of VIDAR-1, which is being conducted at leading university hospitals across Sweden, Denmark, Germany and The Netherlands. Reagan Jarvis, co-founder and Chief Executive Officer of Anocca, said: 'We thank our investors for their strong and continued support as we advance our first TCR-T cell therapy products into the clinic. The team has built a unique discovery platform and in-house manufacturing capability, and we are now excited to see the first products reaching patients with high unmet need.' Johan Andersson, Chairman of Mellby Gård, commented: 'We have been invested in Anocca throughout its preclinical development and are pleased to see the Company transition into a clinical stage biotech. We look forward to seeing Anocca help patients that have limited treatment options today with their innovative approach to T-cell therapies.' SEB Corporate Finance acted as financial advisor to Anocca on the finalisation of the transaction, and Mannheimer Swartling and HWF Advokater have acted as legal advisors. ENDS About Anocca Anocca is a fully integrated clinical-stage biopharmaceutical company that develops libraries of T-cell receptor-engineered T cell (TCR-T) therapies to redefine the treatment of solid tumours and other difficult to treat diseases, including infectious and autoimmune diseases. The company has built a unique discovery engine that uses programmable human cells to recreate and manipulate T cell immunity. These proprietary technologies enable scaling of TCR-T cell therapy development, allowing the systematic generation of libraries of products that represent personalised treatments for the broad patient populations. Anocca currently has the broadest pipeline of TCR-T oncology cell therapy treatments. Anocca operates an advanced research and development infrastructure, underpinned by a custom software ecosystem, AnoccaOS, and an in-house cGMP manufacturing and process development facility. Anocca's TCR-T cell therapies are novel discoveries from its platform and manufactured using non-viral gene editing technology at Anocca's facilities in Södertälje, Sweden. 130+ staff from 40+ nations work at Anocca. About the VIDAR-1 clinical programme VIDAR-1 is designed as a multi-product umbrella trial targeting oncogenic driver mutations in KRAS within pancreatic ductal adenocarcinoma (PDAC). It will investigate up to 20 patients per product in a set of phase I/II studies. Phase I is currently conducted at eight sites in four countries with additional countries and sites in phase II. Patients will be eligible to enrol if they have an HLA, and KRAS mutation, matching an available product. More information about the clinical trial can be found at the EU's clinical trials website. About KRAS and PDAC Mutant KRAS is implicated in pancreatic, lung and colorectal cancers. G12V and G12D mutations in KRAS affect around 90% of pancreatic cancer patients. The five-year survival rate of patients with PDAC is less than 10% (1). Despite recent advances there are no definitive treatments for advanced patients at present (2). References 1. Rawla et al (2019). Epidemiology of Pancreatic Cancer: Global Trends, Etiology and Risk Factors. World J Oncol. 10(1):10–27. doi: 10.14740/wjon1166 2. Hu & O'Reilly (2023). Therapeutic developments in pancreatic cancer. Nat Rev Gastroenterol Hepatol 21, 7–24. doi: 10.1038/s41575-023-00840-w
Associated Press
2 hours ago
- Associated Press
GOGL - Golden Ocean and CMB.TECH - Key dates and information for completion of Merger
HAMILTON, Bermuda, 18 August 2025 – Reference is made to the joint stock exchange announcement on 28 May 2025 by Golden Ocean Group Limited (NASDAQ: GOGL & Euronext Oslo Børs: GOGL) ('Golden Ocean') and NV (NYSE: CMBT & Euronext Brussels: CMBT) (' where it was announced that Golden Ocean would be merging with and into Bermuda Ltd., a wholly-owned subsidiary of with Bermuda as the surviving company, with as the issuer of the merger consideration shares (the 'Merger'). Reference is further made to the announcement that Golden Ocean on 11 August 2025, where it stated that the parties expected closing of the Merger to take place on or around 20 August 2025, subject inter alia to a positive outcome of the Golden Ocean Special General Meeting on 19 August 2025. Consequently, the key dates and information for the completion of the Merger are expected to be as follows: The completion of the Merger will occur prior the scheduled reporting of the second quarter and thereby Golden Ocean will not issue a separate report for the second quarter and first half of the year. The Q2 2025 results for Golden Ocean will be published as part of the Q2 2025 results. About Golden Ocean Golden Ocean is a Bermuda incorporated shipping company specialising in the transportation of dry bulk cargoes. The Golden Ocean fleet consists of 89 vessels, with an aggregate capacity of approximately 13.5 million deadweight tonnes. Golden Ocean's ordinary shares are listed on Nasdaq with a secondary listing on the Euronext Oslo Børs under the ticker symbol 'GOGL'. For further queries, please contact: Peder Simonsen, CEO of Golden Ocean Management AS Telephone: +47 22 01 73 40 Randi Navdal Bekkelund, CFO of Golden Ocean Management AS Telephone: +47 22 01 73 40 This information is subject to the disclosure requirements pursuant to Section 5-12 the Norwegian Securities Trading Act
